De novo cryptogenic hepatitis after sustained eradication of hepatitis C following liver transplantation

Sandeep Mukherjee, J. Rogge, L. K. Weaver, D. F. Schafer

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Patients with recurrent hepatitis C (HCV) after liver transplantation (OLT) are often treated with interferon and ribavirin in an attempt to eradicate HCV and prevent cirrhosis. We report four patients who developed de novo cryptogenic hepatitis following sustained eradication of recurrent HCV, which led to decompensated liver disease in two patients, both of whom required listing for retransplantation. Between September 2000 and October 2001, 38 consecutive patients with recurrent HCV were treated with interferon alpha 2b and ribavirin, of whom eight patients (21%) developed a sustained response to HCV eradication. Four of these patients developed cryptogenic hepatitis, which led to decompensated cirrhosis in two patients. Both patients were listed for retransplantation but died on the waiting list. No etiology for liver disease was identified despite extensive investigations in all four patients including postmortem analysis in the two patients. We hypothesize that these individuals developed an aberrant immune response leading to allograft injury whose severity may be determined by underlying haplotype, degree of immunosuppression, presence/absence of HCV, and duration of treatment. We have not found any similar reports in the literature but anticipate more cases to be reported given the universal use of antiviral therapy for recurrent HCV.

Original languageEnglish
Pages (from-to)1494-1497
Number of pages4
JournalTransplantation Proceedings
Volume36
Issue number5
DOIs
StatePublished - Jun 2004
Externally publishedYes

Fingerprint

Hepatitis C
Liver Transplantation
Hepatitis
interferon alfa-2b
Ribavirin
Liver Diseases
Fibrosis
Waiting Lists
Immunosuppression
Haplotypes
Interferons
Antiviral Agents
Allografts
Wounds and Injuries
Therapeutics

All Science Journal Classification (ASJC) codes

  • Surgery
  • Transplantation

Cite this

De novo cryptogenic hepatitis after sustained eradication of hepatitis C following liver transplantation. / Mukherjee, Sandeep; Rogge, J.; Weaver, L. K.; Schafer, D. F.

In: Transplantation Proceedings, Vol. 36, No. 5, 06.2004, p. 1494-1497.

Research output: Contribution to journalArticle

@article{679940bccbfd47159c718935a208f1b9,
title = "De novo cryptogenic hepatitis after sustained eradication of hepatitis C following liver transplantation",
abstract = "Patients with recurrent hepatitis C (HCV) after liver transplantation (OLT) are often treated with interferon and ribavirin in an attempt to eradicate HCV and prevent cirrhosis. We report four patients who developed de novo cryptogenic hepatitis following sustained eradication of recurrent HCV, which led to decompensated liver disease in two patients, both of whom required listing for retransplantation. Between September 2000 and October 2001, 38 consecutive patients with recurrent HCV were treated with interferon alpha 2b and ribavirin, of whom eight patients (21{\%}) developed a sustained response to HCV eradication. Four of these patients developed cryptogenic hepatitis, which led to decompensated cirrhosis in two patients. Both patients were listed for retransplantation but died on the waiting list. No etiology for liver disease was identified despite extensive investigations in all four patients including postmortem analysis in the two patients. We hypothesize that these individuals developed an aberrant immune response leading to allograft injury whose severity may be determined by underlying haplotype, degree of immunosuppression, presence/absence of HCV, and duration of treatment. We have not found any similar reports in the literature but anticipate more cases to be reported given the universal use of antiviral therapy for recurrent HCV.",
author = "Sandeep Mukherjee and J. Rogge and Weaver, {L. K.} and Schafer, {D. F.}",
year = "2004",
month = "6",
doi = "10.1016/j.transproceed.2004.05.058",
language = "English",
volume = "36",
pages = "1494--1497",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - De novo cryptogenic hepatitis after sustained eradication of hepatitis C following liver transplantation

AU - Mukherjee, Sandeep

AU - Rogge, J.

AU - Weaver, L. K.

AU - Schafer, D. F.

PY - 2004/6

Y1 - 2004/6

N2 - Patients with recurrent hepatitis C (HCV) after liver transplantation (OLT) are often treated with interferon and ribavirin in an attempt to eradicate HCV and prevent cirrhosis. We report four patients who developed de novo cryptogenic hepatitis following sustained eradication of recurrent HCV, which led to decompensated liver disease in two patients, both of whom required listing for retransplantation. Between September 2000 and October 2001, 38 consecutive patients with recurrent HCV were treated with interferon alpha 2b and ribavirin, of whom eight patients (21%) developed a sustained response to HCV eradication. Four of these patients developed cryptogenic hepatitis, which led to decompensated cirrhosis in two patients. Both patients were listed for retransplantation but died on the waiting list. No etiology for liver disease was identified despite extensive investigations in all four patients including postmortem analysis in the two patients. We hypothesize that these individuals developed an aberrant immune response leading to allograft injury whose severity may be determined by underlying haplotype, degree of immunosuppression, presence/absence of HCV, and duration of treatment. We have not found any similar reports in the literature but anticipate more cases to be reported given the universal use of antiviral therapy for recurrent HCV.

AB - Patients with recurrent hepatitis C (HCV) after liver transplantation (OLT) are often treated with interferon and ribavirin in an attempt to eradicate HCV and prevent cirrhosis. We report four patients who developed de novo cryptogenic hepatitis following sustained eradication of recurrent HCV, which led to decompensated liver disease in two patients, both of whom required listing for retransplantation. Between September 2000 and October 2001, 38 consecutive patients with recurrent HCV were treated with interferon alpha 2b and ribavirin, of whom eight patients (21%) developed a sustained response to HCV eradication. Four of these patients developed cryptogenic hepatitis, which led to decompensated cirrhosis in two patients. Both patients were listed for retransplantation but died on the waiting list. No etiology for liver disease was identified despite extensive investigations in all four patients including postmortem analysis in the two patients. We hypothesize that these individuals developed an aberrant immune response leading to allograft injury whose severity may be determined by underlying haplotype, degree of immunosuppression, presence/absence of HCV, and duration of treatment. We have not found any similar reports in the literature but anticipate more cases to be reported given the universal use of antiviral therapy for recurrent HCV.

UR - http://www.scopus.com/inward/record.url?scp=3142536563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3142536563&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2004.05.058

DO - 10.1016/j.transproceed.2004.05.058

M3 - Article

VL - 36

SP - 1494

EP - 1497

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 5

ER -